Skip to main content
OpenTrials
Completed

NCT Number: NCT02882100

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Insight Therapeutics, LLC

Norfolk, Virginia, 23510, United States

About this study

SUMMARY: A random study sample of up to 1000 NHs within 75 miles of the local area of the 121 cities where the CDC performs weekly influenza surveillance (estimated N= 11,239) may be offered the opportunity for participation; the first 1000 eligible to participate and accepting the offer will be enrolled. Participating facilities will be offered vaccine education for residents and staff, but will be randomly allocated to receive aTIV (FLUAD) vaccine or usual care (TIV) vaccination for their residents.

BACKGROUND: Lower respiratory tract infection (LRI), including pneumonia, bronchitis, and tracheobronchitis, is the leading cause of infectious mortality and hospitalization in older adults , and nursing home (NH) residents. Pneumonia and infection often produce attenuated signs and symptoms in older adults, leading to delayed or even misdiagnosis for this population. Diagnosis is further compromised due to few and sporadic clinician visits with nursing home residents, and reduced access to radiology. LRI may or may not directly lead to hospitalization, but LRIs are associated with considerable other morbidity than can result in hospitalization, including exacerbation of underlying cardiopulmonary diseases. Hospitalization rates for NH residents vary considerably between facilities, but the majority of hospitalizations occur during the 12 weeks during which influenza peaks each year.

OBJECTIVES: The primary objective is to estimate the differences in hospitalization rates during influenza season experienced by long-stay nursing home residents, between facilities using adjuvanted trivalent vaccine vs. standard trivalent vaccine. The secondary objective is to estimate the differences in the likelihood of Activities of Daily Living (ADL) functional decline and mortality rates in the study nursing homes, and influenza outbreaks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Long-term care facilities within 75 miles of one of the 121 cities that serve as CDC surveillance sites

Exclusion criteria

  • Facilities that used high dose influenza vaccine in residents over age 65 in previous influenza season (2015-16)
  • Facilities having fewer than 50 long-stay residents
  • Hospital-based facilities
  • Facilities with more than 20% of the population under age 65
  • Facilities not submitting Minimum Data Set (MDS) data

Treatment and study plan

adjuvanted trivalent influenza vaccine

Biological

Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).

Other names: Fluad, aTIV

Trivalent Influenza Vaccine

Biological

Nursing home residents are allocated to receive standard trivalent vaccine (TIV).

Other names: Fluvirin, TIV

Primary outcomes

  1. Hospitalization for a respiratory-related Illness

    Time frame: up to 1 year

    Time to first occurrence of hospitalization for a respiratory-related Illness based upon Medicare inpatient hospital claims

  2. Hospitalization for all causes

    Time frame: up to 1 year

    Time to first occurrence of hospitalization for all-causes

Secondary outcomes

  1. Activities of daily living (ADL) scores

    Time frame: up to 1 year

    Change in activities of daily living (ADL) scores

  2. Mortality

    Time frame: up to 1 year

    Difference in mortality rate

Other outcomes

  1. Influenza outbreaks

    Time frame: up to 1 year

    Difference in occurrence of documented influenza outbreaks

Sponsors and collaborators

Lead sponsor

Insight Therapeutics, LLC

Other

Collaborators

  • Brown University
  • Case Western Reserve University
  • Seqirus

Registry information

Official study title

Adjuvanted Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes

Important dates

Study start
2016
Primary completion
2018
Study completion
2023
First posted
Aug 29, 2016
Registry last updated
Mar 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.